- 
						Phase 2
- 
						 
						 
						
							
- 
					40-85Altersgruppe
- 
					47Standorte
- 
						
						Recruiting
Menü
 
									
                                     Neuropsychiatrische Störungen
									Neuropsychiatrische Störungen
                                
                            Vielen Dank, dass Sie Ihre Frage übermittelt haben. Sie erhalten innerhalb von zwei Werktagen eine Antwort an die von Ihnen angegebene E-Mail-Adresse. Vielen Dank.
Ein Systemfehler ist aufgetreten. Bitte erneut übermitteln
Recruiting
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Key Inclusion Criteria: - Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability Key Exclusion Criteria: - Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any other acute or serious condition that could interfere with assessments during the study or may pose a risk to the participant Note: Other protocol-defined inclusion/exclusion criteria apply
Studienarme
Experimental: BMS-986435
Studienarme
Placebo Comparator: Placebo